TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Frequency of adverse events during iSIL treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Kinetics of the decline in HCV-RNA after 2 weeks of iSIL treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rifampicin Absorption (Ka)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in patient's perception of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total number of patients requiring hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Ability to administer twice daily oral quercetin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of oral quercetin therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of oral quercetin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pigment clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of systemic and dermatologic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic data for washing fluid (Cmax and AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cost evaluation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient time spent obtaining care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time provider spends in direct patient care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pattern of acute on chronic liver cell failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Citrate concentration - pre-filter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Citrate concentration - post-filter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Citrate concentration - dialysate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local-regional failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Inflammatory Lesions (Papules and Pustules)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Demonstrating an Increase in Hgb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of maxillary sinus septa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GP-88 blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fracture rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain frequency
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: CEA mRNA positive circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of culture-confirmed symptomatic influenza infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative Gluteal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported physical health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-reported mental health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative disease-related costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Immunogenicity against influenza strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Titers for DEN Neutralizing Antibodies Types 1, 2, 3 and 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: admission for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biomarkers of β-aminoisobutyric Acid (L-BAIBA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to steady reading in the pulse oximeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in haematological function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Anastomotic leak within 30 days of surgery
Endpoint domain: Adverse events/effects
Primary endpoint: HSV-2 Incidence
Endpoint domain: Mortality/survival
Primary endpoint: Response rate after high-dose therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar crest bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of cases where optical diagnosis derived surveillance intervals concur with histopathology derived surveillance intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polyp detection rate (AI-DETECT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weekly average of complete spontaneous bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total Number of Gd-Enhancing T1-Weighted MRI Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in clinical SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in serum hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of adverse events grade 4 or grade 5
Endpoint domain: Adverse events/effects
Primary endpoint: Graft failure defined as survival to day 42 without absolute neutrophil count greater than or equal to 500/mm3
Endpoint domain: Mortality/survival
Primary endpoint: Wolf Motor function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ahn-Tolosa-Marin Tremor Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Distal muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disability Arm Shoulder Hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nine Holes Peg test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Creatinine levels before surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Creatinine levels after surgery 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Creatinine levels after surgery 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Depression Severity (Change in PHQ-9 Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Between Group Changes in Total Score on the Opening Minds Scale for Health Care Providers (OMS-HC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: safety and toleration
Endpoint domain: Adverse events/effects
Primary endpoint: Unbound Brexpiprazole AUCt,u
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound Brexpiprazole AUC∞,u
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound Maximum Plasma Concentration of Brexpiprazole (Cmax,u)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Tumor Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Whole Grain Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Saturated Fat Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Added Sugars Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gross Motor Function Measure (GMFM-66) - change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and efficacy of VNP40101M
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary protein-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Scale of Suicidal Ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knee Injury Osteoarthritis Outcomes Score (KOOS) Pain Subscore
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Incidence of graded treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of graded laboratory chemistry abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: brain insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients requiring surgical intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Subjects Who Are Inappropriate Shock Free
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects With Unanticipated Severe Adverse Device Effects (Phase I)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Phase I Subjects Where the Ventricular Fibrillation (VF) Detection Time With Protecta Features on is no More Than 2 Seconds Longer Than the VF Detection Time With Protecta Features Off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: True In Vivo Radiation to Rectal Wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HEARTBiT Biomarker Panel Score (BPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse/Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of incorrectly prescribed medicines
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of individuals restarting RAAS inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: sympathovagal score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in FVC (L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrence of Skin and Soft Tissue Infection (SSTI)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of seroma development
Endpoint domain: Adverse events/effects
Primary endpoint: safety and tolerability of IMP321 injections
Endpoint domain: Adverse events/effects
Primary endpoint: dose limiting toxicities of IMP321
Endpoint domain: Adverse events/effects
Primary endpoint: GOSE at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of families diagnosed with CIQTP syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drug Discrimination Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Jebsen Taylor Hand Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Adropin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salusin-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Netrin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nesfatin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excessive weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in diversity index of environment microbial composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in microbiome composition within the environment microbial composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in effort tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family Risk Factors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: On-eye Wettability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anti SARS-CoV-2 antibodies (IgM and IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COVID-19 incidence through serology-based screening and/or compatible symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of reactivation/reinfection for COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Numeric Index of American College of Rheumatology Response (ACR-N)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blood Oxygen Level Dependent (BOLD) Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cortical excitability after Chronic Sleep Deprivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Reaction Times after Chronic Sleep Deprivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in risk taking and financial impulsivity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incontinence episode frequency (IEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (I-QOL) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Metabolic Oxygen Consumption (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Borg Rating of Perceived Exertion (CR100)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Glucose Test Tolerance (OGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative excretion of [14C]-RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics - Tmax of total radioactivity, CC-92480 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics - Cmax of total radioactivity, CC-92480 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual task cost in 10-meter walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual task cost in Timed up and go (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) for dapsone (DDS) and MA-DDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seropositivity for hepatitis C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Extent of the area of microvascular obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Malawi Developmental Assessment Tool Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Calorific Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive finding of hemodynamically significant CAD according to SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive finding of hemodynamically significant CAD according to FFRct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive finding of hemodynamically significant CAD according to ICA +/- iFFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disorder of Initiating and Maintaining Sleep (DIMS) Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Corneal re-epithelialization (initial success)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent corneal re-epithelialization (lasting success)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p53 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NER activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with confirmed etiological diagnosis of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in arterial FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eosinophil Esophagitis symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Susceptibility rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantity of different blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Early postpolypectomy bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Late postpolypectomy bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Total volume of administered analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum dose tolerated of nab-paclitaxel
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity of nab-paclitaxel
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Acute Rejection or HCV Recurrence or Treatment Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From HCV Recurrence Within First Year That Requires HCV Antiviral Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Lymph Node Staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: UPDRS part IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Concentration of Vancomycin in Subcutaneous Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Concentration of Vancomycin in Bone Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Knee Extensor Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Synovial effects of rituximab treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of Correlation Between Ultrasound Results and Pathology Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis B virus Seroprotection after one month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hepatitis B virus Seroprotection after three months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: flashback severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Static Physician Global Assessment Hands and Feet (sPGA - H&F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Static Physician Global Assessment (SPGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dynamic Physician's Global Assessment of Change (dPGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Brief Interview for Mental Status (BIMS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in PTSD Symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete biophysical profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inflammatory and Non-inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants Demonstrating Efficacy Measured by Investigator Global Assessment Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perceptual Reasoning Index (PRI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Progression of Liver Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change From Baseline in ASES Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: alterations in regional brain volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean change in lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Preference for Self or Partner Administration
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Area under the curve from time zero extrapolated to infinity [AUC(0-inf)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All cause morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes